ArticleFrontiers in bioengineering and biotechnology2026
Non-invasive quantification of viability in liver spheroids using deep learning.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of a Novel Fluorescent Marker for Continuous Live Imaging of Preimplantation Embryos.Journal of developmental biology · 2026Article
- Machine learning-supported identification of necrosis in colorectal and pancreatic cancer spheroids.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: We present Neural Viability Regression (NViR), a deep learning-based method that enables real-time, non-invasive quantification of culture viability from microscopy images. Although developed and validated on liver spheroids, the framework includes a retrainable pipeline adaptable to other spheroid types. To demonstrate its applicability, we exposed human liver spheroids to 108 FDA-approved drugs and captured microscopy images over time, using NViR's viability estimates to predict Drug-Induced Liver Injury (DILI). Results: NViR's viability assessments accurately predicted whether a drug induces DILI in humans. Its non-invasive nature enabled frequent viability evaluations throughout experiments, capturing subtle temporal changes while preserving the structural integrity of the cultures and substantially reducing both culture and labor costs. Discussion: The cost-effectiveness and non-destructive characteristics of NViR enable high-frequency, high-throughput viability assessments, positioning it as a tool to enhance liver safety protocols and reduce both the costs and failure rates in drug discovery and development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.